Cairns, J., Arain, S., Challapalli, A. et al. (10 more authors) (2026) Comparative analysis of PSMA-RADS Version 2.0 versus bone uptake metastatic probability (BUMP) score for characterising focal bone uptake on [18F]PSMA-1007 PET/CT in prostate cancer – a multicentre evaluation. European Journal of Nuclear Medicine and Molecular Imaging. ISSN: 1619-7070
Abstract
Purpose Prostate-specific membrane antigen (PSMA) PET/CT is widely used in prostate cancer management, but unspecific bone uptake (UBU) remains a diagnostic challenge particularly with [18F]PSMA-1007. Bone uptake metastatic probability (BUMP) score - a composite imaging-clinical model, was compared with PSMA Reporting and Data System (PSMA-RADS, Version 2) for predicting skeletal metastases in UBU.
Methods A real-world cohort of [18F]PSMA-1007 PET/CT scans performed at three tertiary cancer centres was retrospectively analysed. Bone lesions with focal PSMA uptake were evaluated. SUVmax, CT-derived mean Hounsfield unit and androgen deprivation therapy status were recorded to calculate BUMP score for each lesion. Lesional PSMA-RADS scores were assigned by experienced radiologists. Ground truth was established using follow-up imaging, prostate-specific antigen (PSA) kinetics and multidisciplinary consensus. Receiver operating characteristic (ROC) analyses assessed diagnostic performance.
Results 130 patients (median age 70 years) with 412 bone lesions were analysed; 60.9% (n = 251) of lesions were metastatic. Median SUVmax was higher in malignant than benign lesions: 7.54 (Interquartile range (IQR) 10.3) versus 3.53 (IQR 1.51). BUMP achieved an AUROC of 0.812 (95% CI: 0.636—0.931), the optimal threshold was 0.134 yielding an F1 score of 0.800. PSMA-RADS v2.0 outperformed BUMP with higher sensitivity and specificity (98% and 96%, versus 74% and 80%). In equivocal PSMA-RADS Score 3 lesions (n = 44), BUMP showed reduced discrimination (AUROC 0.61, 95% CI 0.457–0.781).
Conclusion BUMP had good predictive ability for classifying bone metastases but underperformed compared with human-led PSMA-RADS assessment. For equivocal lesions BUMP offered limited added value, highlighting the importance of expert interpretation.
Metadata
| Item Type: | Article |
|---|---|
| Authors/Creators: |
|
| Copyright, Publisher and Additional Information: | © The Author(s) 2026. This is an open access article under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | Diagnostic Techniques; Metastatic; PSMA-1007; Prostate cancer; Prostatic cancer; Urological; Urology |
| Dates: |
|
| Institution: | The University of Leeds |
| Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds) |
| Funding Information: | Funder Grant number Innovate UK fka Technology Strategy Board 10083748 |
| Date Deposited: | 27 Oct 2026 14:24 |
| Last Modified: | 27 Oct 2026 14:24 |
| Status: | Published online |
| Publisher: | Springer Nature |
| Identification Number: | 10.1007/s00259-026-08154-0 |
| Related URLs: | |
| Sustainable Development Goals: | |
| Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:247152 |
Download
Filename: s00259-026-08154-0.pdf
Licence: CC-BY 4.0


CORE (COnnecting REpositories)
CORE (COnnecting REpositories)